StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.74−0.06 (-7.79%)

Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%

Allogene Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Allogene Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$180.32M. For fiscal 2025 it was -$209.32M. The highest annual figure on record is -$180.19M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$209.32M–
FY2024Dec 31, 2024-$273.20M–
FY2023Dec 31, 2023-$327.74M–
FY2022Dec 31, 2022-$335.54M–
FY2021Dec 31, 2021-$180.19M–
FY2020Dec 31, 2020-$258.24M–
FY2019Dec 31, 2019-$202.01M–
FY2018Dec 31, 2018-$192.84M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$46.92M–
Q1 FY2026Mar 31, 2026-$46.09M–
Q4 FY2025Dec 31, 2025-$42.40M–
Q3 FY2025Sep 30, 2025-$44.90M–
Q2 FY2025Jun 30, 2025-$56.82M–
Q1 FY2025Mar 31, 2025-$65.19M–
Q4 FY2024Dec 31, 2024-$60.49M–
Q3 FY2024Sep 30, 2024-$71.77M–
Q2 FY2024Jun 30, 2024-$71.43M–
Q1 FY2024Mar 31, 2024-$69.50M–
Q4 FY2023Dec 31, 2023-$85.11M–
Q3 FY2023Sep 30, 2023-$63.00M–
Q2 FY2023Jun 30, 2023-$80.54M–
Q1 FY2023Mar 31, 2023-$99.09M–
Q4 FY2022Dec 31, 2022-$96.40M-5747.0%
Q3 FY2022Sep 30, 2022-$82.51M–
Q2 FY2022Jun 30, 2022-$76.62M–
Q1 FY2022Mar 31, 2022-$80.01M–
Q4 FY2021Dec 31, 2021$1.71M–
Q3 FY2021Sep 30, 2021-$77.67M–
Q2 FY2021Jun 30, 2021-$71.03M–
Q1 FY2021Mar 31, 2021-$33.20M–
Q4 FY2020Dec 31, 2020-$69.36M–
Q3 FY2020Sep 30, 2020-$68.04M–
Q2 FY2020Jun 30, 2020-$63.16M–
Q1 FY2020Mar 31, 2020-$57.68M–
Q4 FY2019Dec 31, 2019-$64.58M–
Q3 FY2019Sep 30, 2019-$55.01M–
Q2 FY2019Jun 30, 2019-$45.96M–
Q1 FY2019Mar 31, 2019-$36.46M–
Q4 FY2018Dec 31, 2018-$33.05M–
Q3 FY2018Sep 30, 2018-$22.19M–
Q2 FY2018Jun 30, 2018-$135.01M–
Q1 FY2018Mar 31, 2018-$2.60M–

More Allogene Therapeutics figures

See a number that looks wrong?